A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUINCLL- 322)

  • Si Lun Tam, Con (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date2/11/22 → 1/11/24

Keywords

  • Clinical trial
  • Lymphoma